Search details
1.
Rucaparib or Physician's Choice in Metastatic Prostate Cancer.
N Engl J Med
; 388(8): 719-732, 2023 02 23.
Article
in English
| MEDLINE | ID: mdl-36795891
2.
Emergence of BRCA Reversion Mutations in Patients with Metastatic Castration-resistant Prostate Cancer After Treatment with Rucaparib.
Eur Urol
; 83(3): 200-209, 2023 03.
Article
in English
| MEDLINE | ID: mdl-36243543
3.
Rucaparib for the Treatment of Metastatic Castration-resistant Prostate Cancer Associated with a DNA Damage Repair Gene Alteration: Final Results from the Phase 2 TRITON2 Study.
Eur Urol
; 84(3): 321-330, 2023 09.
Article
in English
| MEDLINE | ID: mdl-37277275
4.
What Plasma Can Tell Us When Tissue Cannot: A Case Report of Genomic Testing in mCRPC and Clinical Response to Treatment With the PARP Inhibitor Rucaparib.
Front Oncol
; 12: 951348, 2022.
Article
in English
| MEDLINE | ID: mdl-35978838
5.
A Case Study of Clinical Response to Rucaparib in a Patient with Metastatic Castration-Resistant Prostate Cancer and a RAD51B Alteration.
Curr Oncol
; 29(6): 4178-4184, 2022 06 08.
Article
in English
| MEDLINE | ID: mdl-35735442
6.
Nivolumab plus rucaparib for metastatic castration-resistant prostate cancer: results from the phase 2 CheckMate 9KD trial.
J Immunother Cancer
; 10(8)2022 08.
Article
in English
| MEDLINE | ID: mdl-35977756
7.
Rucaparib in patients presenting a metastatic breast cancer with homologous recombination deficiency, without germline BRCA1/2 mutation.
Eur J Cancer
; 159: 283-295, 2021 12.
Article
in English
| MEDLINE | ID: mdl-34837859
8.
Genomic Analysis of Circulating Tumor DNA in 3,334 Patients with Advanced Prostate Cancer Identifies Targetable BRCA Alterations and AR Resistance Mechanisms.
Clin Cancer Res
; 27(11): 3094-3105, 2021 06 01.
Article
in English
| MEDLINE | ID: mdl-33558422
9.
Response to Rucaparib in BRCA-Mutant Metastatic Castration-Resistant Prostate Cancer Identified by Genomic Testing in the TRITON2 Study.
Clin Cancer Res
; 27(24): 6677-6686, 2021 12 15.
Article
in English
| MEDLINE | ID: mdl-34598946
10.
Genomic Profiles of De Novo High- and Low-Volume Metastatic Prostate Cancer: Results From a 2-Stage Feasibility and Prevalence Study in the STAMPEDE Trial.
JCO Precis Oncol
; 4: 882-897, 2020 Nov.
Article
in English
| MEDLINE | ID: mdl-35050761
11.
Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a BRCA1 or BRCA2 Gene Alteration.
J Clin Oncol
; 38(32): 3763-3772, 2020 11 10.
Article
in English
| MEDLINE | ID: mdl-32795228
12.
Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: Analysis From the Phase II TRITON2 Study.
Clin Cancer Res
; 26(11): 2487-2496, 2020 06 01.
Article
in English
| MEDLINE | ID: mdl-32086346
13.
Reply to Feng Qi, Zicheng Xu, and Qing Zou's Letter to the Editor re: Andrea Loehr, Arif Hussain, Akash Patnaik, et al. Emergence of BRCA Reversion Mutations in Patients with Metastatic Castration-resistant Prostate Cancer After Treatment with Rucaparib. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.09.010.
Eur Urol
; 83(3): e78, 2023 03.
Article
in English
| MEDLINE | ID: mdl-36623951
14.
Loss of heterozygosity as a marker of homologous repair deficiency in multiple myeloma: a role for PARP inhibition?
Leukemia
; 32(7): 1561-1566, 2018 07.
Article
in English
| MEDLINE | ID: mdl-29467487
15.
Genomic loss of heterozygosity and survival in the REAL3 trial.
Oncotarget
; 9(94): 36654-36665, 2018 Nov 30.
Article
in English
| MEDLINE | ID: mdl-30613349
Results
1 -
15
de 15
1
Next >
>>